Alert prescribing of clozapine: a comparison of five drug-drug interaction sources.

IF 3.4 3区医学 Q2 PHARMACOLOGY & PHARMACY

Therapeutic Advances in Drug Safety Pub Date : 2024-12-02 eCollection Date: 2024-01-01 DOI:10.1177/20420986241233842

Jeroen Govaerts, Annelies Verluyten, Filip Bouckaert, Marc A F De Hert, Franciska A M Desplenter

{"title":"Alert prescribing of clozapine: a comparison of five drug-drug interaction sources.","authors":"Jeroen Govaerts, Annelies Verluyten, Filip Bouckaert, Marc A F De Hert, Franciska A M Desplenter","doi":"10.1177/20420986241233842","DOIUrl":null,"url":null,"abstract":"Introduction: Clozapine, an antipsychotic used in the treatment of schizophrenia, is known for its serious side effects. In order to promote patient safety, drug-drug interaction (DDI) databases can be consulted by clinicians. In this study, the degree of consensus between five sources on DDIs with clozapine is determined.Methods: The summary of product characteristics of clozapine, Delphicare interaction database, Stockley's interaction checker, the Lexicomp interaction database, and the interaction database of Clinical Pharmacology are included. By comparing the original categories assigned to interactions with clozapine by the included DDI sources, a degree of consensus between sources is determined. Furthermore, based on the combined information, an evaluation on the severity of each potential interaction is made.Results: One hundred eighty-three potential DDIs with clozapine are retrieved from the five included sources. A consensus between sources is found in 47.5% (n = 87) of DDIs.Conclusion: This study shows major discrepancies between five different sources on DDIs with clozapine. The potential impact of the use of one specific database on patient safety and prescribing behavior could prove to be problematic.","PeriodicalId":23012,"journal":{"name":"Therapeutic Advances in Drug Safety","volume":"15 ","pages":"20420986241233842"},"PeriodicalIF":3.4000,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11613245/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20420986241233842","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Clozapine, an antipsychotic used in the treatment of schizophrenia, is known for its serious side effects. In order to promote patient safety, drug-drug interaction (DDI) databases can be consulted by clinicians. In this study, the degree of consensus between five sources on DDIs with clozapine is determined.

Methods: The summary of product characteristics of clozapine, Delphicare interaction database, Stockley's interaction checker, the Lexicomp interaction database, and the interaction database of Clinical Pharmacology are included. By comparing the original categories assigned to interactions with clozapine by the included DDI sources, a degree of consensus between sources is determined. Furthermore, based on the combined information, an evaluation on the severity of each potential interaction is made.

Results: One hundred eighty-three potential DDIs with clozapine are retrieved from the five included sources. A consensus between sources is found in 47.5% (n = 87) of DDIs.

Conclusion: This study shows major discrepancies between five different sources on DDIs with clozapine. The potential impact of the use of one specific database on patient safety and prescribing behavior could prove to be problematic.

查看原文本刊更多论文

氯氮平的警示处方：五种药物相互作用来源的比较。

氯氮平，一种用于治疗精神分裂症的抗精神病药物，以其严重的副作用而闻名。为了促进患者安全，临床医生可以查阅药物-药物相互作用（DDI）数据库。在本研究中，确定了五个来源对氯氮平ddi的一致程度。方法：总结氯氮平的产品特点，采用Delphicare相互作用数据库、Stockley相互作用检查器、Lexicomp相互作用数据库和临床药理学相互作用数据库。通过比较纳入的DDI来源分配给氯氮平相互作用的原始类别，确定了来源之间的共识程度。在此基础上，对各潜在相互作用的严重程度进行了评价。结果：从5个纳入的来源中检索到含有氯氮平的潜在ddi 183例。47.5% （n = 87）的ddi的来源一致。结论：本研究显示了氯氮平对ddi的5种不同来源之间的主要差异。使用一个特定数据库对患者安全和处方行为的潜在影响可能被证明是有问题的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Therapeutic Advances in Drug Safety Medicine-Pharmacology (medical)

CiteScore

6.70

自引率

4.50%

发文量

审稿时长

9 weeks

期刊介绍： Therapeutic Advances in Drug Safety delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies pertaining to the safe use of drugs in patients. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in drug safety, providing a forum in print and online for publishing the highest quality articles in this area. The editors welcome articles of current interest on research across all areas of drug safety, including therapeutic drug monitoring, pharmacoepidemiology, adverse drug reactions, drug interactions, pharmacokinetics, pharmacovigilance, medication/prescribing errors, risk management, ethics and regulation.